The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?

Just before the end of 2025, an oral version of a GLP-1 drug specifically used for weight management moved much closer to reality. On December 22, the U.S. Food and Drug Administration (FDA) approved ...

Danish pharmaceutical manufacturer Novo Nordisk on Dec. 22 announced that the U.S. Food and Drug Administration (FDA) has ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration (FDA) approving ...

Novo Nordisk plans to quickly launch the pill form of Wegovy but is expected to soon face competition from Eli Lilly.

Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the low priced stocks to buy with high upside potential. On December 8, Wave ...

The FDA approved the first oral GLP-1 for lowering body weight according to a press release from Novo Nordisk. Oral ...

Industry Analysis Examines How FDA's First Oral GLP-1 Approval, Published Clinical Trial Data, and Evolving Telehealth Access ...

The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight loss and to reduce the risk ...

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight. If approved, ...

Today, Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) ...